Cytokinetics Releases SEQUOIA-HCM Findings: Aficamten Shows Promise While Revealing Disparities in Hypertrophic Cardiomyopathy Outcomes Among Diverse Patient Groups

Updated On: May 18, 2025 10:06 am

# Cytokinetics Reveals Aficamten’s Efficacy in New HCM Analyses

Cytokinetics has announced findings from recent SEQUOIA-HCM trial analyses, showcasing the effectiveness of aficamten in treating hypertrophic cardiomyopathy (HCM) across varying symptom severities and geographic locations.

Insights from SEQUOIA-HCM Trial

Cytokinetics, Incorporated recently shared results from two key analyses of the SEQUOIA-HCM trial, which examined aficamten’s impact on patients suffering from symptomatic obstructive HCM. The findings revealed that aficamten maintained effective improvements in exercise capacity and symptoms, regardless of the initial severity of symptoms or the patients’ geographic regions. In patients presenting with mild symptoms, aficamten exhibited a comparable influence on peak oxygen uptake to those with moderate-to-severe symptoms, although the latter group experienced greater improvement overall. Additionally, geographic analyses showed variations in patient characteristics across regions, while the drug’s efficacy and safety profiles remained consistent. A separate analysis of real-world data surfaced disparities in cardiovascular outcomes for female and older patients with non-obstructive HCM, highlighting the urgent need for new therapeutic approaches. Aficamten is currently undergoing regulatory review to potentially enhance HCM treatment options.

Advantages of Aficamten

Data from the SEQUOIA-HCM trial indicate consistent efficacy of aficamten across different symptom severities and geographic areas, suggesting its potential for widespread application.
Aficamten has received Breakthrough Therapy Designation from the FDA, underscoring its promise as a viable therapeutic option for symptomatic obstructive HCM.
The analyses revealed significant disparities in cardiovascular outcomes based on sex and age, reinforcing the need for innovative treatments like aficamten for non-obstructive HCM patients.
Findings from both clinical trials and real-world data could expedite regulatory approvals, positioning Cytokinetics favorably in the HCM treatment market.

Challenges Ahead

Concerns regarding the safety and efficacy of aficamten remain, as the treatment is still under investigation and not yet approved, which may affect market acceptance and patient confidence.
Identified disparities in cardiovascular outcomes among female and older patients suggest the necessity for targeted treatment strategies, pointing to gaps in the efficacy of aficamten across diverse demographics.
While results indicate consistent efficacy, minimal differentiation in treatment effects for patients with varying baseline symptom severity could raise questions about aficamten’s overall value in treating less severe cases.

Frequently Asked Questions

What is Aficamten’s role in treating HCM?

Aficamten is an investigational cardiac myosin inhibitor aimed at improving exercise capacity and alleviating symptoms in patients with hypertrophic cardiomyopathy (HCM).

How does Aficamten affect patients with mild versus severe symptoms?

The impact of aficamten on exercise capacity was consistent across both mild and moderate-to-severe patients, with observable improvements in both categories.

Are there geographical differences in Aficamten’s efficacy?

SEQUOIA-HCM data indicated that aficamten’s efficacy was consistent across various geographic regions, despite differences in baseline characteristics.

What disparities exist in cardiovascular outcomes for non-obstructive HCM patients?

The analysis uncovered disparities in outcomes, particularly affecting females and older individuals, noted for higher rates of stroke and heart failure.

When is Aficamten expected to receive regulatory approval?

Aficamten’s New Drug Application is currently under FDA review, targeting a decision date of December 26, 2025.

$CYTK Insider Trading Activity

$CYTK insiders have executed trades on the open market 43 times in the past six months, with 0 purchases and 43 sales.

Recent insider trading activity includes:

ROBERT I BLUM (President & CEO): 0 purchases and 11 sales, equating to 128,361 shares sold for approximately $5,531,494.
ANDREW CALLOS (EVP, Chief Commercial Officer): 0 purchases and 8 sales, for 61,889 shares sold, totaling around $2,681,219.
FADY IBRAHAM MALIK (EVP Research & Development): 0 purchases and 16 sales, selling 47,666 shares for approximately $2,160,962.
WENDALL WIERENGA: 0 purchases and 3 sales, resulting in 21,484 shares sold for about $842,368.
JOHN T HENDERSON: 0 purchases and 2 sales, selling 4,970 shares for roughly $213,073.
ROBERT ARTHUR HARRINGTON: 0 purchases and 2 sales for 1,350 shares, totaling about $55,993.
MUNA BHANJI sold 1,454 shares for roughly $43,227.

$CYTK Hedge Fund Activity

Recently, 190 institutional investors added to their holdings in $CYTK, while 196 reduced their positions in the last quarter. Notable moves include:

BANK OF AMERICA CORP /DE/: Added 2,483,753 shares (+1133.5%) in Q1 2025, valued at around $99,822,033.
PFM HEALTH SCIENCES, LP: Removed 1,757,192 shares (-100.0%) in Q4 2024, for an estimated $82,658,311.
POINT72 ASSET MANAGEMENT, L.P.: Added 1,553,071 shares (+914.0%) in Q1 2025, valued at approximately $62,417,923.
UBS GROUP AG: Increased holdings by 932,220 shares (+77.6%) in Q1 2025, estimated at $37,465,921.
LOGOS GLOBAL MANAGEMENT LP: Decreased holdings by 900,000 shares (-100.0%) in Q1 2025, valued at about $36,171,000.
PENTWATER CAPITAL MANAGEMENT LP: Reduced holdings by 870,000 shares (-79.8%) in Q1 2025, worth around $34,965,300.
PARADIGM BIOCAPITAL ADVISORS LP: Added 858,664 shares in Q1 2025, for an estimated $34,509,706.

$CYTK Analyst Ratings

In recent months, Wall Street analysts have assessed $CYTK, with two firms issuing buy ratings and none recommending sells. Recent ratings include:

Barclays: “Overweight” rating issued on 04/24/2025.
RBC Capital: “Outperform” rating issued.

# Analysts Weigh In on Cytokinetics: Price Targets and Clinical Insights

## Analyst Price Targets for CYTK

Recent analyses have brought forward new price targets for Cytokinetics, Incorporated (Nasdaq: CYTK). In the past six months, two analysts have issued price targets, yielding a median target of **$61.00**.

Recent price targets include:

– Gena Wang from Barclays set a target of **$55.00** on April 24, 2025.
– An analyst from Morgan Stanley issued a target of **$67.00** on March 7, 2025.

## Clinical Data Release: Aficamten Studies

SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) – Cytokinetics has released findings from two new analyses stemming from the SEQUOIA-HCM study, which evaluates the effects of **aficamten** on patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). These analyses were featured at the European Society of Cardiology Heart Failure 2025 Congress, contributing valuable insights into treatment effectiveness across different patient demographics.

Dr. Stephen Heitner, Vice President and Head of Clinical Research at Cytokinetics, commented on the findings: “These analyses demonstrate that the effects of aficamten on exercise capacity, symptoms, hemodynamics, and cardiac biomarkers are consistent across patients, regardless of baseline symptom severity and geographic region.”

### Insights on Aficamten in Patients with Varying Symptom Severity

The SEQUOIA-HCM analysis involved 282 patients categorized by symptom severity. Patients with mild symptoms (n=118) and those with moderate-to-severe symptoms (n=150) showed comparable improvements in peak oxygen uptake (pVO₂), with an increase of **1.6 mL/kg/min** in mild and **1.8 mL/kg/min** in moderate-to-severe groups respectively. Both groups reported enhancements in their Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), particularly noted in the moderate-to-severe group.

Interestingly, by the end of treatment, **54%** of mild symptom patients and **36%** of moderate-to-severe patients became asymptomatic. While safety and tolerability profiles were similar to placebo in both groups, these findings highlight the drug’s efficacy independent of initial symptom severity.

### Geographic Consistency in Aficamten’s Effectiveness

Another analysis evaluated how aficamten’s effectiveness varied across geographic regions. Participants from SEQUOIA-HCM were grouped into three categories: Europe (including Israel), North America, and China, showing similar responses to treatment despite baseline demographic differences. Key measurements such as peak VO₂ and adverse event rates remained consistent across all regions.

### Real-World Data on Non-Obstructive HCM Outcomes

In a separate health economics and outcomes research (HEOR) analysis, data were drawn from 9,842 patients diagnosed with non-obstructive HCM. This study revealed differences in cardiovascular outcomes based on age and sex. Female patients had higher rates of stroke, heart failure, and cardiovascular hospitalization compared to male patients.

Overall, the data suggest critical insights into treatment impacts for varieties of hypertrophic cardiomyopathy, emphasizing the need for a nuanced approach to patient care.

—

For further analysis and updates on CYTK, visit their designated information pages.# Study Reveals Gender and Age Disparities in Heart Disease Outcomes

Research highlights significant differences in health outcomes for female and older patients with non-obstructive hypertrophic cardiomyopathy (HCM). In the study, female patients exhibited a higher risk of rehospitalization (Relative Risk (RR) 1.15) compared to male patients (all p < 0.01). However, they were less prone to experience atrial fibrillation (RR 0.83) and ventricular tachycardia (RR 0.69) (p < 0.001). Additionally, younger patients showed lower risks across several conditions, including atrial fibrillation, stroke, heart failure, cardiovascular hospitalizations, and rehospitalizations when compared to patients aged 75 and older (all p < 0.001).

Furthermore, all-cause mortality was notably higher in female patients compared to their male counterparts (p = 0.002). The study found that older patients had the highest all-cause mortality rates, with figures of 16.6% for those aged 75 and above, 8.3% for ages 65 to 74, 3.5% for 55 to 64, 3.1% for 40 to 54, and 1.4% for those aged 18 to 39. These findings underline the disparities in morbidity and survival, signifying a compelling need for innovative treatments to alleviate the clinical burden on these populations.

About Aficamten

Aficamten is an investigational selective small molecule cardiac myosin inhibitor discovered through a rigorous chemical optimization program. The drug aims to diminish the number of active actin-myosin cross bridges during each cardiac cycle, effectively alleviating the myocardial hypercontractility associated with HCM. In preclinical studies, aficamten successfully reduced myocardial contractility by binding to cardiac myosin at a specific allosteric site, preventing myosin from achieving a force-producing state.

The development of aficamten is focused on enhancing exercise capacity, measured by peak oxygen uptake (pVO₂), and alleviating symptoms in HCM patients. It was evaluated in the SEQUOIA-HCM clinical trial, a pivotal Phase 3 trial targeting symptomatic obstructive hypertrophic cardiomyopathy (HCM). Following its positive results, aficamten received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for symptomatic HCM and from the National Medical Products Administration (NMPA) in China for symptomatic obstructive HCM.

Currently, aficamten is under assessment in ACACIA-HCM, a Phase 3 clinical trial involving patients with non-obstructive HCM, as well as in CEDAR-HCM, which focuses on a pediatric population with obstructive HCM. An open-label extension study, FOREST-HCM, is also underway involving various HCM patients.

This communication summarizes new data from the European Society of Cardiology Heart Failure 2025 Congress regarding the clinical development of aficamten. As of now, aficamten is not approved by any regulatory authority, and its safety and efficacy have yet to be established. The FDA is currently reviewing a New Drug Application (NDA) for aficamten, with a Prescription Drug User Fee Act (PDUFA) target action date set for December 26, 2025.

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is characterized by an abnormal thickening of the heart muscle (myocardium), which leads to a reduced ability of the left ventricle to relax and fill with blood. This condition can restrict the heart’s pumping function and manifest in symptoms like chest pain, dizziness, shortness of breath, or fainting during exertion. HCM is the most prevalent monogenic inherited cardiovascular disorder in the U.S., affecting approximately 280,000 diagnosed patients, with an estimated 400,000-800,000 who remain undiagnosed.

Around two-thirds of patients have obstructive HCM (oHCM), where the muscle thickening causes left ventricular outflow tract (LVOT) obstruction. The remaining third has non-obstructive HCM (nHCM), characterized by thickened muscle without blood flow obstruction. Patients with HCM are at heightened risk for cardiovascular complications such as atrial fibrillation, stroke, and mitral valve disease. These patients are also vulnerable to life-threatening ventricular arrhythmias, making HCM a leading cause of sudden cardiac death, particularly among younger populations and athletes.

About Cytokinetics

Cytokinetics is a biopharmaceutical company specializing in cardiovascular treatments. With over 25 years of innovation in muscle biology, the company is preparing for potential regulatory approval and commercialization of aficamten, which yielded promising results in the SEQUOIA-HCM trial. Cytokinetics is also advancing other products like omecamtiv mecarbil, for heart failure with reduced ejection fraction, as well as CK-586 and CK-089 for additional cardiac and muscular conditions.

Forward-Looking Statements

This communication contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Cytokinetics disclaims any intent or obligation to update these statements and seeks protection under the Act’s Safe Harbor provisions.

# Cytokinetics Addresses Future of Aficamten and Regulatory Approvals

This communication includes forward-looking statements about the anticipated treatment effects and potential benefits of Aficamten and other drug candidates, as well as Cytokinetics’ ability to secure regulatory approval for Aficamten in the U.S. and internationally. However, there is no guarantee that these expectations will be met, and actual results may differ significantly due to various risks and uncertainties. These risks relate to Cytokinetics’ business as outlined in filings with the Securities and Exchange Commission.

It’s important to note that forward-looking statements are not guarantees of performance. Instead, they may reflect management’s current expectations, which can change in response to new information, market conditions, or other factors after the date of this release. Cytokinetics will not update these statements unless legally required.

Trademarks

CYTOKINETICS® and the CYTOKINETICS logo are registered trademarks of Cytokinetics in the United States and select other countries.

For Further Information:

Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

References:

Maron MS, et al. Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUOIA-HCM Trial. European Heart Journal, 2025. https://doi.org/10.1093/eurheartj/ehaf364
Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021;64(19):14142–14152. https://doi.org/10.1021/acs.jmedchem.1c01290
CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575
Symphony Health 2016-2021 Patient Claims Data DoF;
Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.
Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.
Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21.